NEULANDLAB - Swing Trade Analysis with AI Signals
Back to ListHere’s the structured swing trade analysis for NEULANDLAB based on the given parameters
📊 Swing Trade Rating: 4.4
| Stock Code | NEULANDLAB | Market Cap | 22,114 Cr. | Current Price | 17,220 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 60.9 | Book Value | 1,454 ₹ | Dividend Yield | 0.20 % | ROCE | 26.6 % |
| ROE | 21.5 % | Face Value | 10.0 ₹ | DMA 50 | 16,113 ₹ | DMA 200 | 14,798 ₹ |
| Chg in FII Hold | -0.44 % | Chg in DII Hold | 1.12 % | PAT Qtr | 213 Cr. | PAT Prev Qtr | 40.4 Cr. |
| RSI | 58.8 | MACD | 258 | Volume | 27,005 | Avg Vol 1Wk | 33,135 |
| Low price | 11,500 ₹ | High price | 19,748 ₹ | PEG Ratio | 2.00 | Debt to equity | 0.16 |
| 52w Index | 69.4 % | Qtr Profit Var | 666 % | EPS | 283 ₹ | Industry PE | 32.1 |
NEULANDLAB shows strong swing trade potential. The current price of 17,220 ₹ is above both the 50 DMA (16,113 ₹) and 200 DMA (14,798 ₹), reflecting bullish technical strength. RSI at 58.8 suggests neutral-to-slightly overbought momentum, while MACD at 258 confirms bullish momentum. Fundamentals are robust with ROCE at 26.6%, ROE at 21.5%, and EPS at 283 ₹. Valuation is stretched (P/E 60.9 vs industry 32.1, PEG 2.00), but quarterly PAT growth (+666%) adds confidence. Institutional flows are mixed with FII outflows (-0.44%) and DII inflows (+1.12%).
Optimal Entry Price: 16,800–17,000 ₹, near support levels.
Exit Strategy if Holding: Consider profit booking around 19,200–19,500 ₹, before resistance at 19,748 ₹.
✅ Positive
- 📈 Strong ROCE (26.6%) and ROE (21.5%).
- 💹 EPS of 283 ₹ reflects strong earnings visibility.
- 📊 PAT surged from 40.4 Cr. to 213 Cr. (+666%).
- 🏦 Debt-to-equity ratio of 0.16 indicates financial stability.
- 📉 Stock trading above both 50 DMA and 200 DMA, showing technical strength.
⚠️ Limitation
- 📉 Very high P/E (60.9 vs industry 32.1).
- 📊 PEG ratio of 2.00 suggests expensive growth prospects.
- 📉 Dividend yield of 0.20% offers negligible income appeal.
- 📉 RSI at 58.8 suggests risk of short-term correction.
🚨 Company Negative News
- 📉 Decline in FII holding (-0.44%), showing reduced foreign investor confidence.
🌟 Company Positive News
- 📈 DII holding increased (+1.12%), reflecting strong domestic institutional support.
- 💹 Quarterly profit growth of 666% demonstrates exceptional operational performance.
🏭 Industry
- 📊 Industry P/E at 32.1 is much lower than NEULANDLAB’s, suggesting peers may be more attractively priced.
- 💊 Pharma and specialty chemicals sector benefits from rising demand in healthcare and exports.
📌 Conclusion
⚖️ NEULANDLAB is fundamentally strong and technically bullish, making it a good candidate for swing trading. Entry near 16,800–17,000 ₹ with a target exit around 19,200–19,500 ₹ offers favorable risk-reward. Strong profitability and institutional support add confidence, though high valuation and negligible dividend yield warrant caution.
Would you like me to extend this with a pharma sector overlay or a peer comparison to put NEULANDLAB’s swing trade potential in broader context?